Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Kedudukan dalam Saham #29770
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Harga Saham
$0.1200389
Modal Pasaran
$19.57M
Perubahan (1 hari)
-3.25%
Perubahan (1 tahun)
-40.45%
Negara
FR
Perdagangan GenSight Biologics S.A. (SIGHT)

Kategori

Sejarah harga saham bagi GenSight Biologics S.A. (SIGHT)
Harga penutupan tertinggi: $0.11 pada 2026-08-01

Harga penutupan terendah: $8.93 pada 2016-07-01
Sejarah harga saham GenSight Biologics S.A. dari 2016 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2026 (TTM) 0.82%
2025 -61.96%
2024 -40.41%
2023 -85.79%
2022 -40.62%
2021 -23.84%
2020 252.34%
2019 -43.91%
2018 -36.71%
2017 -20.44%
2016 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
$527.89 35.09%
US
$996.61 51.72%
NL
$117.42 -19.34%
AU
$742.10 6.97%
CH
$1.07K -5.58%
KR